Feature

Diabetes drugs with cardiovascular benefits broaden cardiology’s turf

Publish date: November 9, 2016

 

On Twitter @mitchelzoler

Pages

Recommended Reading

VIDEO: Newer type 2 diabetes drugs pose no significant heart failure risk
Type 2 Diabetes ICYMI
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin
Type 2 Diabetes ICYMI
Empagliflozin’s triumph respins FDA’s diabetes drug mandate
Type 2 Diabetes ICYMI
AHA: Empagliflozin for T2D reduces heart failure endpoints
Type 2 Diabetes ICYMI
FDA cancels REMS for rosiglitazone
Type 2 Diabetes ICYMI
Primary care endures in heart failure management
Type 2 Diabetes ICYMI
Incretin-based diabetes drugs don’t raise heart failure risk
Type 2 Diabetes ICYMI
FDA adds safety warnings to certain type 2 diabetes medications
Type 2 Diabetes ICYMI
No rise in serious HF seen in patients taking saxagliptin or sitagliptin
Type 2 Diabetes ICYMI
Statement warns of drugs causing or exacerbating heart failure
Type 2 Diabetes ICYMI